Ex-NIH, Sanofi leaders nab Merck support for their biotech’s Epstein-Barr vaccine
Gary Nabel, Anthony Fauci and other NIH leaders called for a vaccine to prevent Epstein-Barr virus-associated cancers in 2011. Nabel went on to lead scientific operations at Sanofi, where he worked with former NIH director Elias Zerhouni on programs that included early research on an EBV vaccine.
After leaving the French Big Pharma, they formed a new biotech, ModeX Therapeutics, and in-licensed the Sanofi intellectual property on their EBV work. Now, they’re teaming up with Merck to bring the vaccine candidate into the clinic next year for infectious mononucleosis (commonly referred to as mono), Nabel tells Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.